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Abstract
Tumor genomic instability and selective treatment pressures result in clonal disease evolution; molecular stratification for
molecularly targeted drug administration requires repeated access to tumor DNA. We hypothesized that circulating plasma
DNA (cpDNA) in advanced cancer patients is largely derived from tumor, has prognostic utility, and can be utilized for
multiplex tumor mutation sequencing when repeat biopsy is not feasible. We utilized the Sequenom MassArray System and
OncoCarta panel for somatic mutation profiling. Matched samples, acquired from the same patient but at different time
points were evaluated; these comprised formalin-fixed paraffin-embedded (FFPE) archival tumor tissue (primary and/or
metastatic) and cpDNA. The feasibility, sensitivity, and specificity of this high-throughput, multiplex mutation detection
approach was tested utilizing specimens acquired from 105 patients with solid tumors referred for participation in Phase I
trials of molecularly targeted drugs. The median cpDNA concentration was 17 ng/ml (range: 0.5–1600); this was 3-fold
higher than in healthy volunteers. Moreover, higher cpDNA concentrations associated with worse overall survival; there was
an overall survival (OS) hazard ratio of 2.4 (95% CI 1.4, 4.2) for each 10-fold increase in cpDNA concentration and in
multivariate analyses, cpDNA concentration, albumin, and performance status remained independent predictors of OS.
These data suggest that plasma DNA in these cancer patients is largely derived from tumor. We also observed high
detection concordance for critical ‘hot-spot’ mutations (KRAS, BRAF, PIK3CA) in matched cpDNA and archival tumor tissue,
and important differences between archival tumor and cpDNA. This multiplex sequencing assay can be utilized to detect
somatic mutations from plasma in advanced cancer patients, when safe repeat tumor biopsy is not feasible and genomic
analysis of archival tumor is deemed insufficient. Overall, circulating nucleic acid biomarker studies have clinically important
multi-purpose utility in advanced cancer patients and further studies to pursue their incorporation into the standard of care
are warranted.
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Introduction
The development of cancer is primarily due to genetic
aberrations that drive oncogenesis and determine the clinical
manifestations of tumors; these may also impact response to
treatment [1]. Our improved knowledge of the underlying biology
of cancer and the availability of modern biotechnological tools is
beginning to lead to the successful development of novel antitumor
molecular therapeutics, as well as a better recognition of
mechanisms of resistance [2,3]. Notable examples include KRAS
mutations in colorectal tumors predicting resistance to anti-
epidermal growth factor receptor (EGFR) targeting monoclonal
antibodies (cetuximab [ImClone and Bristol-Myers Squibb]; and
panitumumab [Amgen]) [4,5], and KIT mutations predicting
antitumor responses to imatinib (Novartis) in gastrointestinal
stromal tumors [6]. Molecular analysis of these genomic aberra-
tions is usually conducted on archival tumor tissue due to ethical
and safety challenges associated with repeated biopsies. However,
in view of the potential for genomic instability, concerns remain,
about the validity of this approach of analyzing archival tumor
tissue, rather than rebiopsying tumor for molecular analyses at
each therapeutic decision point. For example, it is unclear if the
analysis of archival tumor biopsies taken many years and
frequently multiple therapies previously, sufficiently reflects disease
biology at time of treatment. Rebiopsy of a selected tumor lesion
may not, however, provide sufficient information on intra-patient
disease molecular heterogeneity and rebiopsying multiple lesions
remains clinically impractical. Improved strategies to pursue
patient molecular stratification are urgently needed.
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We set out to optimize benefit for patients with advanced solid
tumors referred for Phase I clinical trials by allocating specific
targeted therapies to patients who harbor tumor molecular
aberrations targeted by the agent in question [2,3,7]. We
evaluated tumors obtained from these patients with the high
throughput Sequenom MassArray platform utilizing the Onco-
Carta mutation panel (version 1.0; Sequenom, San Diego, CA).
This panel utilizes pre-designed and pre-validated mass spectro-
metric SNP genotyping technology for the parallel multiplex
analyses of 238 simple and complex mutations across 19 common
oncogenes, minimizing the amount of specimen required and
maximizing sensitivity [8]. It has previously been used successfully
for the screening of mutations in formalin-fixed paraffin-embed-
ded (FFPE) tumor tissue [9] [10].
An alternative source of tumor DNA is circulating plasma DNA
(cpDNA) [11], which may be easily and repeatedly extracted from
plasma and may be tumor-derived [11,12], with cpDNA
concentrations associating with disease burden and progression
[13]. Studies have also demonstrated the feasibility of mutation
detection from cpDNA in patients with advanced cancer
[14,15,16,17,18]. We set out to explore the potential utility of
multiplex mutation detection from cpDNA with the high
throughput Sequenom MassArray platform utilizing the Onco-
Carta mutation panel (v1.0) to determine if this may be used as an
adjunct to tissue biopsies to enrich and support tumor data for
patient selection. Secondary objectives were to investigate if the
measurement of cpDNA concentrations has prognostic value.
Materials and Methods
Clinical specimens
Patients with late stage advanced solid tumors who were
referred to the Drug Development Unit in the Royal Marsden
NHS Foundation Trust between September 2009 and August
2010, and who were eligible for a Phase I trial were included in
this study. All patients provided written informed consent for
genetic analysis of their tumors and plasma samples prior to
participation in this study. Eight mls of peripheral blood were
sampled in a BD Vacutainer Cell Preparation Tube (CPT)
containing sodium heparin, which permits plasma and mononu-
clear cell separation during a single centrifugation step. The tube
was inverted a minimum of 8 times to ensure thorough mixing of
the sample, and then centrifuged at 1800 g for 15 min. The
resultant plasma supernatant was transferred to a clean tube and
stored at 280uC until analysis. In addition, 20 healthy volunteers
provided 8 ml of blood for analysis using this method. Corre-
sponding FFPE samples (primary and/or metastatic sites) for each
patient were also requested. The relevant regulatory and
independent ethics committee (National Research Ethics Service
(NRES) Committee London-Chelsea, United Kingdom) approved
this study prior to trial commencement.
DNA isolation and quantification
For the analyses of tumor samples, hemotoxylin- and eosin-
stained slides were reviewed by a board-certified pathologist (K.T.)
to ensure adequate viable tumor and to determine the tumoral
zone to core. DNA from FFPE specimens was extracted from
1 mm cores when possible or from 10 mm unstained sections with
smaller biopsies using the QIAamp DNA FFPE Tissue Kit
(Qiagen, Valencia, CA, USA), according to the manufacturer’s
recommendations. The extracted DNA was subsequently eluted in
30 ml of ATE buffer and stored at 220uC until further analysis.
DNA was quantified using the Nanodrop 1000 Spectrophotometer
(Thermo Scientific).
For cpDNA extraction, plasma was thawed at ambient
temperature and cpDNA extracted from 2 ml of plasma using a
QIAamp DNA Blood Midi Kit (Qiagen, Valencia, CA, USA),
according to the manufacturer’s instructions, with the following
modifications: for each 2 ml sample of plasma, an additional
centrifugation step (16000 g, 5 min, RT) was added before the
extraction procedure in order to eliminate cellular debris from the
plasma. At the end of the procedure, the DNA was eluted in
100 ml of AE elution buffer. DNA concentration was measured
with fluorescent staining, using the Quant-iTTM Pico-GreenH
double stranded DNA (dsDNA) Assay Kit (Invitrogen, Carlsbad,
CA) and the SynergyHT microplate reader (Biotek). DNA from
the cancer cell lines analyzed was extracted from pellets using the
QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA), according
to the manufacturer’s recommendations. For purposes of com-
parison, all cpDNA concentrations presented in this manuscript
are expressed as ng/ml of plasma.
Mass Spectrometry TypePLEX technology and OncoCarta
panel (v1.0)
The OncoCarta panel (v1.0) consists of 24 pools of primer pairs and
extension primers, and has the capacity to detect 238 mutations in 19
genes. The protocol provided by Sequenom (San Diego, CA) was
followed with minor modifications. The amount of DNA added to the
polymerase chain reaction (PCR) was 20 ng per reaction for FFPE
DNA samples. For plasmaDNA samples, 30 ml of DNAwere added to
30 ml of pure water, and used for the OncoCarta panel (v1.0)
processing. DNA was amplified using the OncoCarta PCR primer
pools, unincorporated nucleotides were inactivated by shrimp alkaline
phosphatase (SAP), and a single base extension reaction was performed
using extension primers that hybridize immediately adjacent to the
mutations and a custommixture of nucleotides. Salts were removed by
the addition of a cation exchange resin. Multiplexed reactions were
spotted onto SpectroCHIP II arrays, and DNA fragments were
resolved by MALDI-TOF on the Compact Mass Spectrometer
(Sequenom, San Diego, CA).
Data analysis
Data analysis was performed using MassArray Typer Analyzer
software 4.0.4.20 (Sequenom), which facilitates visualization of data
patterns and the raw spectra. Typer automates the identification of
mutants by comparing ratios of the wild type peak to that of all
suspected mutants and generates an OncoMutation report detailing
specific mutations and the ratios of wildtype and mutation peaks. All
mutations from the Oncomutation report were reviewed manually by 2
blinded operators, with selected reviewed mutations from the
OncoMutation report compared and confirmed to be concordant.
Manual review of mutations on all OncoCarta spectra was performed
to identify ‘‘real’’ mutant peaks from salt peaks or other background
peaks. Statistical analyses are detailed in the Supplemental Methods S1.
FFPE mutation confirmation
KRAS mutations were also detected using the Therascreen
KRAS mutation kit (Qiagen, Germany) based on Amplification
Refractory Mutation System (ARMS)-Scorpion PCR [19]. BRAF
V600E mutations were also detected using the Capillary
electrophoresis-single strand conformation analysis (CE-SSCA).
Further details are provided in the Supplemental Methods S1.
Results
Patient characteristics
A total of 105 patients referred for phase I trial participation
were enrolled between September 2009 and August 2010
Oncogenic Mutations in Tumor and Plasma Specimens
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(Table 1; Table S1). One patient was subsequently found to be
ineligible for Phase I trials and therefore this study as he had not
exhausted all lines of available antitumor treatments. The different
tumor types represented in the remaining 104 patients were
colorectal cancer (CRC) (n = 25), breast cancer (n = 19), melano-
ma (n = 15), ovarian cancer (n = 15), castration resistant prostate
cancer (CRPC) (n = 11) and other tumor types (n = 19), including
non-small cell lung cancer (NSCLC), mesothelioma, sarcoma,
glioblastoma, adenocarcinoma of unknown primary (ACUP),
cholangiocarcinoma, and cervical, endometrial, duodenal, esoph-
ageal, pancreatic and renal cancers (Table 1).
Of the 104 patients analyzed in the study, FFPE primary tumor
samples were obtained for 69 (66%) subjects, with FFPE nodal
and/or metastatic tumor samples being available for a further 31
(30%) patients. cpDNA was collected from 101 (97%) patients; it
was not possible to draw blood from 1 patient for technical reasons
and blood was not collected from 2 patients due to logistical errors.
A total of 60 patients died during follow up, while data for 44
patients were censored for purposes of this publication. The
median follow up time was 5.8 months (range 0.3–17.5) (Table 1).
DNA serial dilution experiments for assay development
Dilutions of DNA extracted from the KRAS mutant HCT116
human colon cancer cell line showed that the KRAS G13D
mutation was reproducibly detectable by the OncoCarta v1.0
panel at DNA concentrations as low as 40 ng/ml (Figure S1).
cpDNA was also collected from healthy volunteers (Table 2); in
these samples, the cpDNA concentration was found to be low:
median 6.5 ng/ml of plasma (range 4.5–13.3 ng/ml of plasma),
and no mutations were detected in any sample. A patient with
advanced breast cancer who had very high cpDNA levels
(1600 ng/ml of plasma) was found to have a PIK3CA mutation
in both FFPE and cpDNA samples; serial dilutions of this cpDNA
showed that the PIK3CA mutation was detectable up to a
concentration of 2.5 ng/ml of plasma utilizing this assay.
Plasma cpDNA concentration levels and mutation
detection
The overall median cpDNA concentration was 17 ng/ml in
these patients with advanced tumors (range: 0.5–1600) (Figure 1;
Table S1). The median cpDNA concentration was 18 ng/ml
(range: 5–230) for patients with CRC; 7 ng/ml (range: 2–50) for
patients with melanoma, 17 ng/ml (range: 0.5–1600) for patients
with breast cancer, 15 ng/ml (range: 4–49) for patients with
ovarian cancer and 53 ng/ml of plasma (range: 7–1177) for
patients with CRPC who had the highest plasma DNA
concentrations.
Matched plasma and FFPE were available for analysis from 84
patients. A total of 42 mutations were detected in either or both
FFPE tumor and cpDNA specimens obtained from these patients
(Table 3; Table S1; Figures S2A–S2D). The overall concor-
dance in detected mutations between FFPE and cpDNA
Table 1. Patient characteristics (n = 104).*
Parameter No. of patients* (%)
Gender
Male 45 (43.3%)
Female 59 (56.7%)
Median age, years 56 (range 22–75)
Tumor types
Colorectal cancer 25 (24.0%)
Breast cancer 19 (18.3%)
Melanoma 15 (14.4%)
Castration resistant prostate cancer 11 (10.6%)
Ovarian cancer 15 (14.4%)
Other** 19 (18.3%)
ECOG PS at screening
0 36 (34.6%)
1 62 (59.6%)
2 6 (5.8%)
Min Median Max Mean sd
Follow-up time (months) 0.3 5.8 17.5 6.1 3.7
No. of metastatic sites 0 1 2 3 4+
No. of patients 4 30 41 19 10
Albumin 23 34 43 34.4 4.2
LDH 100 202.5 3531 300.3 370.2
cpDNA (ng/mL)*** 0.5 17.3 1600 55.4 196.1
*One patient was subsequently found to be ineligible for this study as he had not exhausted all lines of available antitumor treatments.
**Includes non-small cell lung cancer (NSCLC), mesothelioma, sarcoma, glioblastoma, adenocarcinoma of unknown primary (ACUP), cholangiocarcinoma, and cervical,
endometrial, duodenal, esophageal, pancreatic and renal cancers.
***cpDNA was collected from 101 (97%) patients; it was not possible to draw blood from 1 patient for technical reasons and blood was not collected from 2 patients
due to logistical errors.
doi:10.1371/journal.pone.0047020.t001
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specimens was 60% (25 of 42 detected mutations) (Table 3).
Nonparametric ROC analyses were used to assess the limit of the
Sequenom platform to detect OncoCarta panel mutations in
cpDNA (Figure 2A). The concentration of cpDNA with the
optimal ability to detect a mutation was 29.95 ng/ml (Likelihood
ratio = 7.3043). The AUC calculated was 0.8075 (95% CI 0.6552–
0.9598). Figure 2B shows the different types of mutations in a
range of tumor types at the respective cpDNA concentrations they
were detected at.
Correlation with patient outcome. The median overall
survival (OS) for all patients was 7.9 months (95%CI 5.8, 9.2). Patients
were categorised into low and high cpDNA concentration groups
based on the maximum healthy volunteer cohort DNA concentration
of 13.3 ng/ml; 61 patients were classified as having high cpDNA
concentrations with 40 having low levels. The median OS in patients
categorised as having low cpDNA concentrations was 10.5 months
(95%CI 6.0, NC), while those in the high cpDNA concentration group
had a median OS of 6.5 months (95%CI 4.5, 8.4) (logrank p=0.0383)
(Figure 3A). As a continuous variable, there was anOS hazard ratio of
2.4 (95% CI 1.4, 4.2) for each 10-fold increase in cpDNA
concentration (Figure 3B).
Correlation with RMH prognostic score. We have
recently prospectively validated a prognostic score (RMH score)
for patients participating in Phase I clinical trials based on the
combination of three prognostic factors: serum albumin less than
35 g/L; lactate dehydrogenase (LDH) greater than the upper limit
of normal (ULN); and two or more sites of metastases. The
presence of each of these variables associated with worsening
outcome [20]. The mean cpDNA concentration was higher in
patients with a worse RMH prognostic score (F[3,98] = 9.97,
p,0.0001); Post-tests revealed a significant positive linear trend
between log10(cpDNA) and RMH score (beta = 0.247, p,0.0001)
(Figure 4).
Correlation with univariate and multivariate
analysis. Univariate testing was used to determine significant
predictors of overall survival, which included cpDNA concentra-
tion as a continuous variable (HR 2.4 per 10-fold increase, 95% CI
1.4–4.2), albumin ,35 g/L (logrank p= 0.0003), and ECOG
performance status equal to 2 (logrank p= 0.0007). When cpDNA,
albumin and performance status were incorporated into a
multivariate model, all three parameters were found to be
independent predictors of survival (Table 4). The number of
Table 2. Characteristics of healthy volunteers (n = 20).
Parameters n (%)
Gender
Male 7 (35%)
Female 13 (65%)
Median age, years 34 (range 25–52)
n min median max mean sd
cpDNA (ng/ml) 20 4.5 6.4 13.3 7.4 2.9
doi:10.1371/journal.pone.0047020.t002
Figure 1. DNA concentrations (ng/mL) classified by tumor types. Box and whisker plots showing 25th, 50th and 75th percentiles, upper and
lower adjacent values (whiskers) and Tukey outliers (N). P value is for a two-sided unpaired t-test on log10 DNA concentrations using Welch’s
correction for unequal variances.
doi:10.1371/journal.pone.0047020.g001
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metastatic sites was not found to be a significant predictor of
survival in the univariate analysis and was therefore excluded from
the multivariate model.
Mutational detection and concordance between FFPE
and cpDNA
Colorectal cancer. Of 25 patients with CRC, cpDNA
samples were obtained from all patients, while FFPE tumor
samples were available for analysis for 22 patients. Overall,
mutations were detected in 15 of 22 (68.2%) available FFPE
tumors and 14 of 25 (56%) cpDNA specimens (Table S1).
Specifically, KRAS, BRAF and PIK3CA mutations were detected in
10 (45%), 3 (14%) and 2 (9%) tumor specimens, respectively.
Comparatively, 9 (36%) KRAS, 3 (12%) BRAF and 3 (12%) PIK3CA
mutations were detected in cpDNA samples.
Concordance in the detection of mutations between matched FFPE
archival tumors and cpDNA specimens by Sequenom OncoCarta
analyses was 70% (7 of 10 patients) for KRAS and 100% (3 of 3 patients)
for BRAFmutational status (Table 3). No patients with wildtype KRAS
or BRAF tumor tissue genotypes had mutations in their respective
cpDNA. Five patients had detectable PIK3CA mutations in either or
both FFPE tumor and/or cpDNA: 1 patient had a Q546K mutation
detected in both FFPE tissue and cpDNA; 1 patient had an E545K
mutation detected only in FFPE, but not cpDNA; 1 patient had an
E542K mutation detected in a liver metastasis (FFPE), but not in the
primary tumor (FFPE) or cpDNA; 1 patient had E545K detected only
in plasma but not FFPE; and 1 patient had a Q546K mutation found
in cpDNA but no FFPE specimen was available. The recently reported
oncogenic AKT1 E17Kmutation [21] was detected in 1 patient in both
tissue and plasma. No mutations in other tested oncogenes were
detected.
There was 90% (9 of 10 KRAS mutated samples) concordance
for FFPE tumoral KRAS mutational status between the OncoCarta
panel and the ARMS-Scorpion PCR platforms. The BRAF
concordance between the OncoCarta panel and CE-SSCA
method was 100% (3 of 3 BRAF mutated samples).
Melanoma. Of the 15 patients with melanoma, FFPE tumor
samples were available for analysis for 10 patients, while cpDNA
samples were obtained from all 15 patients. Overall, mutations
were detected in 8 of 10 (80.0%) available FFPE tumors and 6 of
15 (40%) cpDNA specimens (Table S1).
BRAF, NRAS and MET mutations were detected in 5 (50%), 3
(30%) and 1 (10%) of 10 FFPE tumor specimens, respectively, and
3 (20%), 2 (13.3%) and 2 (13.3%) of 15 cpDNA samples,
respectively. Concordance in the detection of mutations between
matched FFPE and cpDNA was 60% (3 of 5 patients) for BRAF,
66.7% for NRAS (2 of 3 patients) and 100% for MET mutational
status (1 of 1 patient) (Table 3). Another MET mutation, T992I,
was found in one cpDNA sample, but no FFPE tumor specimen
was available. No patients with wildtype tumor tissue genotypes
had mutations in their respective cpDNA.
There was 100% concordance (5 of 5 samples) for the BRAF
mutational status between the OncoCarta panel and CE-SSCA
method.
Breast cancer. FFPE tumor samples and cpDNA samples
were available for analysis for all 19 patients with breast cancer.
Overall, mutations were detected in 5 of 19 (26.3%) FFPE tumors
and 4 of 19 (21.1%) cpDNA specimens (Table S1).
The PIK3CA H1047R mutation was detected in 4 of 19 (21.5%)
tumor specimens and 3 of 19 (15.8%) cpDNA samples, with
concordance between 3 of 4 (75%) matched FFPE and cpDNA
specimens (Table 3). The AKT1 E17K mutation was detected in 1
patient in both FFPE tissue and cpDNA. No mutations in any of
the other oncogenes studied were detected with the OncoCarta
panel. No patients with wildtype tumor tissue genotypes had
mutations in their respective cpDNA.
Castration resistant prostate cancer. Of the 11 patients
with CRPC, cpDNA samples were obtained from all patients,
while FFPE tumors were available for 8 patients. Overall,
mutations were detected in 3 of 8 (37.5%) FFPE tumors, and 3
of 11 (27.3%) cpDNA specimens (Table S1).
PIK3CA, HRAS and AKT1 (all n = 1) mutations were detected in
FFPE tumor specimens, while NRAS, PIK3CA and AKT1 (all n = 1)
mutations were found in cpDNA samples. The corresponding
FFPE tumor PIK3CA and AKT1 mutations were found in the
cpDNA samples, but the FFPE tumor HRAS mutation was not
found in the matched cpDNA sample (Table 3). The Q61K
NRAS mutation was found in 1 cpDNA specimen, but not in the
corresponding FFPE tumor sample.
Ovarian cancer. Of the 15 patients with advanced ovarian
cancer, cpDNA samples were obtained from all patients, while
FFPE tumor samples were available for 14 patients. Overall,
mutations were detected in 5 of 14 (35.7%) FFPE tumors, and 0 of
14 (0%) cpDNA specimens (Table S1).
KRAS mutations (G12V and G13D) (n = 3) and the PIK3CA
H1047R mutation (n= 1) were detected in FFPE tumor samples,
but no mutations were found in any cpDNA samples (Table 3).
One patient with ovarian carcinosarcoma had a KIT P585P
mutation detected in FFPE, but not in cpDNA.
Other tumor types. Of the remaining 19 patients with a
range of tumor types, cpDNA samples were obtained from 17
patients, while FFPE tumors were available for 12 patients.
Table 3. Concordance in detected mutations between paired FFPE tumors and cpDNA.
BRAF KRAS NRAS HRAS MET AKT PIK3CA KIT
Colorectal 3/3 (100%) 7/10 (70%) - - - 1/1 (100%) 1/3 (33.3%) -
Melanoma 3/5 (60%) - 2/3 (66.7%) - 1/1 (100%) - - -
Breast - - - - - 1/1 (100%) 3/4 (75%) -
Prostate - - 0/1 (0%) 0/1 (0%) - 1/1 (100%) 1/1 (100%) -
Ovarian - 0/2 (0%) - - - - 0/1 (0%) 0/1 (0%)
ACUP - - 1/1 (100%) - - - - -
Cholangiocarcinoma - - 0/1 (0%) - - - - -
Duodenal carcinoma - 0/1 (0%) - - - - - -
Total = 25/42 (60%) 6/8 (75%) 7/13 (54%) 3/6 (50%) 0/1 (0%) 1/1 (100%) 3/3 (100%) 5/9 (55.6%) 0/1 (0%)
doi:10.1371/journal.pone.0047020.t003
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The NRAS G12D mutation was found in both FFPE tumor and
plasma from a patient with ACUP (Table 3). The NRAS G13R
mutation was detected in the plasma, but not in FFPE tumor from
a patient with cholangiocarcinoma. The KRAS G12D mutation
was found in FFPE tumor, but not in plasma from a patient with
duodenal cancer. No mutations were detected in the other
patients, including no epidermal growth factor receptor (EGFR)
mutations in the 5 patients with NSCLC.
Concordance in mutation detection between FPFE and
cpDNA for primary tumor or metastatic specimens
When considering all patients with matched samples, including
those with no mutations detected (n= 83), the concordance in
detecting mutations between FFPE and cpDNA was higher in
metastases (83.3% of 18 specimens) compared with primary tumor
(78.5% of 65 specimens). When considering only patients with
mutations detected in at least blood and/or primary tumor
(n= 40), the concordance in detecting mutations between FFPE
and cpDNA was again higher in metastases (70.0% of 10
specimens) compared with primary tumor (53.3% of 30 speci-
mens). However, because of the difference in the number of
primary tumor (n = 65) and metastatic (n = 18) specimens
obtained, we are unable to draw any statistical conclusions from
these data.
Discussion
This study has demonstrated, for the first time, the feasibility of
multiplex detection of tumor DNA mutations utilizing the
multiplex OncoCarta panel from both DNA extracted from FFPE
archival tumor tissue and cpDNA. We have shown that total
cpDNA levels in patients with advanced cancers are, in general,
significantly higher than those in healthy volunteers, with the
highest concentrations found in patients with advanced prostate
and breast cancers, although this difference was not significant in
melanoma and ovarian cancer (Figure 1). The maximum
Figure 3. Relationship between cpDNA concentration and
survival. (3A) Kaplan-Meier graph showing survival curves by cpDNA
concentration in 101 patients with advanced solid tumors. Patients in
the unfavorable category had concentrations greater than a healthy
volunteer cohort maximum of 13.3 ng/ml (logrank p= 0.0383). (3B)
Survivor function estimated from univariate Cox regression showing
predicted survival curves for a range of cpDNA concentrations. A hazard
ratio of 2.4 (p = 0.002) is depicted between adjacent curves.
doi:10.1371/journal.pone.0047020.g003
Figure 2. cpDNA concentrations for mutational detection by
Sequenom OncoCarta panel (v1.0). 2A: Nonparametric ROC
analyses were used to assess the limit of the Sequenom platform to
detect OncoCarta panel mutations in cpDNA. Each dot on the graph
corresponds to the sensitivity and specificity at one of the observed
concentrations. Mutations were considered ‘available for detection’ if
they were detected in the patient’s FFPE tissue. Mutations were
detected in FFPE samples from 37 patients. The concentration of
cpDNA with the optimal ability to detect a mutation is 29.95 ng/ml
(Likelihood ratio = 7.3043). The AUC calculated is 0.8075 (95% CI 0.6552–
0.9598). Patients whose FFPE was unavailable or tested negative for
mutations were excluded from the analysis. The specificity reference
lines for quartiles of DNA concentrations are indicated in red dashed
lines. 2B: Graph showing the types of mutations and cpDNA
concentrations at which they were detected in different tumors.
Mutations were detected in six oncogenes. Symbols represent different
tumor types.
doi:10.1371/journal.pone.0047020.g002
Oncogenic Mutations in Tumor and Plasma Specimens
PLOS ONE | www.plosone.org 6 November 2012 | Volume 7 | Issue 11 | e47020
concentration detected in healthy volunteers was found to split
patients into two groups that were associated with significantly
different prognoses; patients in the low cpDNA group had a
significantly higher OS relative to those in the high cpDNA group
[11,13,22]. Furthermore, the cpDNA concentration remained
highly prognostic for OS in a multivariate analyses utilizing the
prognostic biomarkers for the Phase I trial patient population that
we have previously described [20]. We have also shown a
correlation between cpDNA concentrations and the prognostic
score that we have previously described to predict the outcome of
patients referred for Phase I trial participation; cpDNA concen-
tration, albumin ,35 g/L and performance status had prognostic
value in our series of patients as independent predictors of survival.
These data overall indicate that cpDNA in this patient population
is largely tumor derived, although this may be generated by both
malignant and stromal cells.
The Sequenom OncoCarta panel has also enabled us to analyze
more than 230 known mutation ‘hot-spots’ mutations in over a
hundred patients in a high throughput fashion. The OncoCarta
panel covers a large and increasing number of oncogenes and can
be adapted to include additional genes of interest. It allows tumor
mutation detection even with minimal amounts of tumor DNA,
poor tissue preservation and the presence of significant amounts of
normal DNA. Next generation sequencing technology will allow
more DNA coverage and data acquisition, allowing the sequenc-
ing of hundreds of full length genes, which will be critical to the
study of genes where mutations can be found in multiple disparate
locations, as is the case for many tumor suppressor genes such as
BRCA1, BRCA2, p53 and PTEN.
As we move towards the development of molecularly targeted
agents for selected populations of patients, it is crucial that the
molecular characterization of tumors for the prediction of efficacy
to targeted therapies is incorporated into early clinical trials [2,3].
Such an approach can increase the odds of individual patient
benefit, decreasing the number of patients receiving ineffective
therapies and expediting the clinical qualification of predictive
biomarkers. Archival tumor tissue, frequently taken many years
before, is often used for these analyses. Tumor rebiopsy remains
uncommon, although it is feasible as demonstrated in the first
BATTLE lung cancer adaptive trial [23]. Nevertheless, mandating
multiple repeated tumor rebiopsies poses logistical, fiscal and
ethical issues, while slowing down trial accrual and not addressing
the issue of intra-patient lesion-to-lesion heterogeneity. Rebiopsy
and cpDNA analyses can both address concerns surrounding
tumor genomic instability and clonal molecular evolution due to
therapeutic selection pressures while also potentially interrogating
Figure 4. Relationship between cpDNA concentration and RMH prognostic score. Scatterplot showing the relationship between cpDNA
concentration and RMH prognostic score. There was a significant positive linear trend between log10(cpDNA) and RMH score (beta = 0.252,
p,0.0001).
doi:10.1371/journal.pone.0047020.g004
Table 4. Univariate and multivariate analysis.
Univariate logrank
Multivariate Cox regression
n=101
Variable p HR 95% CI p
cpDNA ng/mL (Cox regression) 2.43 (1.39–4.25) p = 0.002 1.98 1.01–3.88 0.045
albumin ,35 g/L 0.0003 1.86 1.01–3.42 0.047
ECOG PS=2 0.0007 8.05 2.53–25.65 ,0.0005
doi:10.1371/journal.pone.0047020.t004
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the intra-patient heterogeneity issue. Testing cpDNA has multiple
advantages, being inexpensive, relatively simple to test, more
acceptable to the patient and easily analyzed repeatedly permitting
the study of mechanisms of drug resistance at tumor progression.
Our data now support a concerted effort to develop cpDNA multi-
purpose biomarker studies that can be incorporated into the
standard of care.
The origin of DNA in the plasma of patients with cancer
remains undefined, but may be derived from tumor cell fragments,
microparticles or exosomes, or indeed from circulating free DNA
[11,22,24]. Our studies show that the sensitivity of this technology
to detect tumor mutations in cpDNA depended, in part, on
cpDNA concentrations. Work carried out by other investigators
through cell mixing experiments have shown that for KRAS
mutations G12C, G1A, and G13C, the sensitivity of the
Sequenom Oncocarta assay is 2.5% and for G13D it is 10% of
mutant DNA [25].
The discordance in results observed between archival tumors
and cpDNA specimens could be due to several reasons: 1) Poor
mutation detection in cpDNA due to low cpDNA concentrations;
2) Poor DNA quality in the FFPE archival sample; 3) potential
false positive results in either sample type; 4) true disease
heterogeneity. Overall, however, there was high concordance rate
for FFPE KRAS mutation detection rate between the Sequenom
OncoCarta platform and the ARMS Scorpion and CE-SSCA
methods suggesting that poor DNA quality in the FFPE sample
was not a major issue. In addition, the mutational concordance
rates between FFPE tumor samples and cpDNA observed in our
study are comparable to other published methods. For example, in
patients with NSCLC, the PCR-RFLP method could detect KRAS
mutations in plasma with a concordance rate between FFPE
tumors and cpDNA of 76.7% [26]. In patients with CRC, the
BEAMing method has been demonstrated to detect KRAS
mutation in plasma in 50% of patients with mutation detected
in FFPE [27]. In patients with melanoma, the BEAMing platform
has also been shown to detect BRAF mutations with a 75%
concordance rate, although in the reported study, data were not
available for up to a third of the tumor samples [14]. Overall,
nevertheless, it is important to note that inter-assay (FFPE versus
plasma) discordance may potentially be due to true tumor
heterogeneity. Low cpDNA concentrations can however limit
the detection of mutations in plasma, but this challenge may
potentially be resolved by utilizing higher starting plasma volumes.
It is important to note that in this study, several patients had
cpDNA levels below that of healthy volunteers, so any tumor-
derived circulating DNA in these patients is likely to be heavily
diluted by genomic sequence from normal or stromal tissues.
In conclusion, we envision that biomarker studies such as that
described above can have a potential impact on molecular
stratification and patient care. We therefore recommend a
concerted effort by the cancer community in order to develop
analytically validated assays on cpDNA that can be clinically
qualified for more broad utilization [2,3]. We envision that the
analyses of cpDNA will become part of cancer patient standard of
care. Finally, with whole exome and cancer genome analyses
becoming increasingly feasible and affordable, studies to analyze
the feasibility of a deep sequencing approach from the plasma of
cancer patients are now warranted [28].
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